BGF MDI 320/14.4/9.6 μg + GFF MDI 14.4/9.6 μg
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
COPD (Chronic Obstructive Pulmonary Disease)
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Trial Timeline
Feb 21, 2024 → Mar 7, 2028
NCT ID
NCT06283966About BGF MDI 320/14.4/9.6 μg + GFF MDI 14.4/9.6 μg
BGF MDI 320/14.4/9.6 μg + GFF MDI 14.4/9.6 μg is a phase 3 stage product being developed by AstraZeneca for COPD (Chronic Obstructive Pulmonary Disease). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06283966. Target conditions include COPD (Chronic Obstructive Pulmonary Disease).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06283966 | Phase 3 | Recruiting |
Competing Products
20 competing products in COPD (Chronic Obstructive Pulmonary Disease)